48 items found in 6 pages
Unlocking the SDGs - India ep
The SDGs and India (special edition episode with UCL partners in India – Professor P V Madhusudhan Rao (Indian Institute of Technology Delhi) and Professor Sumit Malhotra (All India Institute of Medical Sciences Delhi (AIIMS).
7
11/19/2024
Episode 1: Introduction to Together We Create Series 2 - what UCL’s social scientists gain from collaborative partnerships
What do we mean when we talk about collaborative social science? Why is collaborative research useful? What are the standout themes of the collaborative projects featured in this second season of Together We Create? In this episode, we discuss these questions and more with Professor Carey Jewitt, Chair of UCL's Collaborative Social Science Domain. Carey Jewitt is Professor of Technology and Learning at the UCL Knowledge Lab, based in the Department of Culture, Communication and Media at the Institute of Education. She brings her interdisciplinary training from fine art and media, sociology, and multimodal discourse to research how the use of digital technologies shapes people’s interaction, communication, and learning in a variety of contexts. For the podcast transcript, details of our other podcasts and activities: http://tinyurl.com/mubmxu4n
2
2/28/2024
Octopus (part 4): Involvement of people affected by MS with Susan Scott
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years. The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. In the final part, we explore the role of people affected by MS in the Octopus trial. Susan Scott, a pharmaceutical publications specialist and Octopus patient representative, shares her involvement in the trial and explains how PPI has benefited Octopus so far.
14
11/8/2023
Octopus (part 2): Introducing the trial with Jeremy Chataway
Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years. The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. Part 2 of the series explores our Octopus trial in depth. Professor Jeremy Chataway, lead investigator of Octopus, discusses its novel design, the treatments it will test, and the criteria for people to take part. He also explains the data researchers will collect and analyse to find out if a treatment is working.
1
10/24/2023
Optimising treatments with the new MAMS-ROCI design
Innovative platform designs present an opportunity to run faster and more efficient clinical trials. Clinical trials methodology is a research area that looks at how to improve the design, conduct, and analysis of clinical trials. It focuses on developing and implementing new methods to help run trials faster and more efficiently, that will ultimately accelerate the discovery of new treatments. In this episode, methodologist Matteo Quartagno tells us about a new clinical trial design called MAMS-ROCI. It is a type of multi-arm multi-stage design that compares a range of different treatment durations, doses or frequencies to identify the optimal one.
1
9/20/2023
Neonatal infections (part 2): How the NeoSep1 trial will help treat sick newborns
Neonatal sepsis is a life-threatening infection that affects up to 3 million babies per year globally. In an effort to identify better treatments, the NeoSep1 clinical trial evaluates new antibiotic combinations for newborn babies with sepsis. To learn more about the trial, we speak to Adrie Bekker and Cristina Obiero, principal investigators of the trial in South Africa and Kenya, Reenu Thomas, a neonatologist from South Africa, and Francesca Schiavone, the clinical project manager of the NeoSep1 trial in London.
1
6/8/2023
Neonatal infections (part 1): The NeoOBS study and the global challenge of neonatal sepsis
214,000 newborn babies die of sepsis caused by infections that are resistant to antibiotics every year. This is a major problem worldwide, but disproportionally affects low- and middle- income countries. Reenu Thomas and Adrie Bekker, two neonatologists from South Africa, and Francesca Schiavone, clinical project manager at the MRC CTU at UCL in London, discuss the challenges of treating neonatal sepsis and present the results from an observational study (NeoOBS), which assessed mortality rates of babies with sepsis.
2
5/17/2023
The STREAM2 trial: how should we treat multi-drug resistant tuberculosis?
For World TB Day, this episode explores the global burden of tuberculosis (TB) and how growing antibiotic resistance can complicate treatment options. Andrew Nunn, a Professor of Epidemiology, discusses his work on the STREAM2 trial, which investigated how treatment for multi-drug resistant TB could be shortened and made more acceptable for patients. Further information is available on the STREAM Stage 2 study page at www.mrcctu.ac.uk and results from STREAM2 are published open access in The Lancet.
6
3/23/2023
123456 >